Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
מצבים רפואיים
Gastric Cancer
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
The Affliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
Contact: Study coordinator (Weiwei Chen)Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Contact: Study coordinator (Yanqiao Zhang)Contact: Study coordinator (Dan Su)Henan Cancer Hospital, Zhengzhou, Henan, China
Contact: Study coordinator (Xiaobing Chen)Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Contact: Study coordinator (Xianglin Yuan)The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Contact: Study coordinator (Xiaojun Xiang)The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
Contact: Study coordinator (Jinghua Sun)Contact: Study coordinator (Lingling Xu)Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Jun Zhang)West China Hospital of Sichuan University, Chengdu, Sichuan, China
Contact: Study coordinator (Hongfeng Gou)The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Contact: Study coordinator (Xuefen Lei)
מובילי המחקר
Ruihua Xu, MD
Principal Investigator
Sun Yat-sen University